Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
Sponsor

Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Italy Via Adamello 16, 20139 Milan, Italy

About the sponsor

Research activity in colon cancer centers on stage III and high-risk stage II disease, with attention to operable locoregional cases and post-surgical management.

  • Post-surgical risk stratification
  • Liquid biopsy
  • ctDNA-guided treatment

The studies focus on identifying residual disease after surgery and guiding adjuvant treatment decisions through circulating tumor DNA and blood-based molecular markers.

About Specializations

Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets runs clinical trials in conditions such as Colorectal cancer stage II, Colorectal cancer stage III, Colorectal cancer metastatic, Breast cancer stage III, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Colorectal cancer stage II+1

Recruiting

Study on Colon Cancer Treatment Using Disodium Levofolinate and Drug Combination for Patients with Operable Stage III and High-Risk Stage II Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Colorectal cancer metastatic

Not recruiting

Study of Pembrolizumab and Temozolomide for Patients with Metastatic Colorectal Cancer Who Have Not Responded to Standard Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Breast cancer stage III+2

Not recruiting

Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Colorectal cancer stage II+1

Not recruiting

Study of Drug Combination Treatment (Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan) Guided by Liquid Biopsy Testing in Patients with Stage III and High-Risk Stage II Colon Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.